Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to measure the efficacy of flexible dosing of dapoxetine in a setting similar to routine clinical practice.


Clinical Trial Description

This is a prospective, interventional study to evaluate efficacy and safety of flexible dose dapoxetine as Premature Ejaculation (PE) Therapy. The total study duration will be 16 weeks, composed of a 2-week pretreatment phase and a 12-week open-label treatment phase, followed by a telephone contact two weeks after Week 12 to follow-up adverse events. At Visit 1 (Screening) standardized assessment tool or patient questionnaires will be used to determine which of those patients with erectile dysfunction/premature ejaculation are eligible to participate in this study. Once enrolled the patient and his partner are expected to attempt sexual intercourse a minimum of 2 times (at least 24 hours apart) and to complete a Baseline Event Log. Starting at Visit 2 (Baseline), the patient (and partner) will complete the Premature Ejaculation Profile (PEP) at the beginning of every treatment visit for the duration of the study. Patients will be started on study drug instructed to take 1 tablet of dapoxetine 30 mg, as needed, 1 to 3 hours prior to sexual activity. The need for adjustments in the dose of dapoxetine, as well as to assess the occurrence of adverse events and concomitant therapy use will be assessed approximately every 4 weeks. Patients will complete Treatment Event Logs during each dosing throughout the open-label treatment phase. Patients who have their dose increased to 60 mg, will be scheduled for a telephone consultation 1 week after to determine how the dose change is tolerated. At Visit 5 (Final Visit/Week 12/Early Termination), the patients and partners will complete several standardized assessment questionnaires have all final visit procedures performed and schedule a telephone follow up contact to evaluate any adverse events. The starting dose of dapoxetine is 30 mg (one 30-mg tablet), taken approximately 1 to 3 hours prior to sexual activity. The dose may be increased after 4 weeks to 60 mg taken. The maximum recommended dosing frequency is once every 24 hours. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01063881
Study type Interventional
Source Johnson & Johnson Pte Ltd
Contact
Status Completed
Phase Phase 3
Start date May 2010
Completion date June 2011

See also
  Status Clinical Trial Phase
Completed NCT01021670 - An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride Phase 4
Completed NCT00324948 - Topical Alprostadil for Female Sexual Arousal Disorder Phase 2
Recruiting NCT02624648 - Effects of Lepidium Meyenii Walp on Sexual Function in Postmenopausal Women Phase 1
Completed NCT05692960 - Women's Interventions for Sexual Health: WISH N/A
Completed NCT01188720 - Sexual Health on Antidepressants Through Physical Exercise N/A
Completed NCT00692419 - Pain, Sexual Dysfunction, and Depression in Hemodialysis Patients N/A
Completed NCT00451165 - Bowel, Urinary and Sexual Function After Laparoscopic Colorectal Surgery N/A
Recruiting NCT04604951 - Below the Belt: Non-invasive Neuromodulation to Treat Bladder, Bowel, and Sexual Dysfunction Following Spinal Cord Injury N/A
Recruiting NCT04512287 - PRP for Treatment of Peyronie's Disease Phase 2
Completed NCT02381912 - Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer N/A
Completed NCT00698035 - Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients Phase 2
Completed NCT00443027 - Effect Of Menstrual Cycle On Vaginal Blood Flow In Pre-Menopausal Healthy Women. Phase 1
Completed NCT00443248 - Vaginal Heat Wash-out (HWO) in 4 Groups of Women (Pre- and Postmenopausal With and Without Female Sexual Arousal Disorder (FSAD)). Phase 1
Completed NCT03241524 - Consistency of Questionnaires to Evaluating Sexual Functions in Young Healthy Women N/A
Terminated NCT03018106 - Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction Phase 4
Completed NCT04364841 - Body Image and Sexuality After Bariatric Surgery
Completed NCT03592121 - Study to Investigate the Effect of AB-101 in Breast Cancer Survivors Early Phase 1
Completed NCT00482664 - The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder. Phase 2
Recruiting NCT05456919 - Quality of Sexual Function in BRCA Mutated Women
Recruiting NCT06308614 - Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women Phase 2